ReviewExpert review of anti-infective therapy2010
Pathogenesis and management of Kawasaki disease.
Review in Expert review of anti-infective therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 6 syntheses or guidelines pooled it, 151 citations in OpenAlex.
- COVID-19 and New Onset IgA Vasculitis: A Systematic Review of Case Reports.Journal of emergency nursing · 2022Pooled it
- Multisystem inflammatory syndrome in pediatric COVID-19 patients: a meta-analysis.World journal of pediatrics : WJP · 2021Pooled it
- A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis.Current rheumatology reports · 2020Pooled it
- Tumor necrosis factor-α-308 polymorphism is not associated with Kawasaki disease: A meta-analysis of case-control studies.Medicine · 2019Pooled it
- Guideline
- A meta-analysis of the biomarkers associated with coronary artery lesions secondary to Kawasaki disease in Chinese children.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2011Pooled it
- Urinary exosomal microRNAs in Kawasaki disease and their changes after treatment.Pediatric research · 2026Article
- Cutaneous Clues in Kawasaki Disease: Clinical Implications and Differential Diagnosis with Multisystem Inflammatory Syndrome in Children.Journal of clinical medicine · 2026Review
- Linkage between IL-23 and coronary arterial lesions in pediatric patients with Kawasaki disease.Frontiers in pediatrics · 2026Article
- Atypical Kawasaki Disease in a 5-month-old Infant.Annals of African medicine · 2025Article
- Kawasaki Disease Presenting Uncommonly with Torticollis: A Case Report.Clinical case reports · 2025Article
- Predictive modeling of consecutive intravenous immunoglobulin treatment resistance in Kawasaki disease: A nationwide study.Scientific reports · 2025Article
- Atypical Kawasaki disease with giant coronary artery aneurysms in a 2-month-old boy: a case report.Journal of medical case reports · 2024Article
- COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.Cell communication and signaling : CCS · 2024Review
- Article
- Pediatric multisystem inflammatory syndrome associated with COVID-19: Insights in pathogenesis and clinical management.World journal of virology · 2023Review
- Kawasaki Disease Shock Syndrome Presented with Giant Coronary Artery Dilatation - Presentation of Two Cases and a Literature Review.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2022Article
- Ambient Air Pollution and Kawasaki Disease in Korean Children: A Study of the National Health Insurance Claim Data.Journal of the American Heart Association · 2022Article
- Deep Learning-Based Approach to Automatically Assess Coronary Distensibility Following Kawasaki Disease.Pediatric cardiology · 2022Article
- Predictive Role of IL-2R and IL-10 in the Anti-inflammatory Response and Antiplatelet Therapy of Kawasaki Disease: A Retrospective Study.Mediators of inflammation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Kawasaki disease (KD) is an acute systemic inflammatory illness of young children that can result in coronary artery aneurysms, myocardial infarction and sudden death in previously healthy children. Clinical and epidemiologic features support an infectious cause, but the etiology remains unknown four decades after KD was first identified by Tomisaku Kawasaki. Finding the cause of KD is a pediatric research priority. We review the unique immunopathology of KD and describe the current treatment. New research has led to identification of viral-like cytoplasmic inclusion bodies in acute KD tissues; this finding could lead to identification of the elusive etiologic agent and result in significant advances in KD diagnosis and treatment. Current management of acute KD is based upon prospective, multicenter treatment trials of intravenous immunoglobulin (IVIG) with high-dose aspirin. Optimal therapy is 2 g/kg IVIG with high-dose aspirin as soon as possible after diagnosis during the acute febrile phase of illness, followed by low-dose aspirin until follow-up echocardiograms indicate a lack of coronary abnormalities. The addition of one dose of intravenous pulse steroid has not been shown to be beneficial. For the 10-15% of patients with refractory KD, few controlled data are available. Options include repeat IVIG (our preference), a 3-day course of intravenous pulse methylprednisolone, or infliximab (Remicade). Patients with mild-to-moderate coronary abnormalities should receive an antiplatelet agent such as low-dose aspirin (3-5 mg/kg/day) or clopidogrel (1 mg/kg/day up to 75 mg), and those with giant (approximately 8 mm diameter) or multiple coronary aneurysms should receive an antiplatelet agent with an anticoagulant such as warfarin or low-molecular-weight heparin. Acute coronary obstruction requires acute thrombolytic therapy with a surgical or percutaneous interventional procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.